Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease

Singh, Namita; Rabizadeh, Shervin; Jossen, Jacqueline; Pittman, Nanci; Check, Morgan; Hashemi, Ghonche; Phan, Becky L.; Hyams, Jeffrey S.; Dubinsky, Marla

doi:10.1097/mib.0000000000000865

Cited by 102 publications

(93 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vedolizumab also benefits one-third of patients with IBD who failed to previous anti-TNF therapy in a phase III trial [17]. Vedolizumab is efficacious and safe in pediatric IBD patients too, with UC patients experiencing earlier and higher rates of remission than CD patients in a multicenter experience trial [18]. Mongersen, an oral SMAD7 antisense oligonucleotide, which targets SMAD7 to increase the activity of TGF β , induces significantly higher rates of remission and clinical response than placebo in patients with active CD in a phase II trial [19].…”

Section: Recent Advances In Biologics Treatment and Clinical Trialmentioning

confidence: 99%

Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Guan

Zhang

2017

Mediators of Inflammation

133

View full text Add to dashboard Cite

Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, where they drive and regulate multiple aspects of intestinal inflammation. The imbalance between proinflammatory and anti-inflammatory cytokines that occurs in IBD results in disease progression and tissue damage and limits the resolution of inflammation. Targeting cytokines have been novel strategies in the treatment of IBD. Recent studies show the beneficial effects of anticytokine treatments to IBD patients, and multiple novel cytokines are found to be involved in the pathogenesis of IBD. In this review, we will discuss the recent advances of novel biologics in clinics and clinical trials, and novel proinflammatory and anti-inflammatory cytokines found in IBD with focusing on IL-12 family and IL-1 family members as well as their relevance to the potential therapy of IBD.

show abstract

Section: Recent Advances In Biologics Treatment and Clinical Trialmentioning

confidence: 99%

Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Guan

Zhang

2017

Mediators of Inflammation

133

View full text Add to dashboard Cite

show abstract

“…High baseline abundance of Bifidobacterium , Clostridium colinum , Eubacterium rectale , uncultured Clostridiales and Vibri o, together with a lower abundance of Streptococcus mitis , predicted response to anti‐TNF therapy in one study (Table S4). Recently, a lower baseline dysbiosis index and higher abundance of Faecalibacterium prausnitzii were associated with subsequent clinical and endoscopic response, however these findings lacked statistical significance …”

Section: Resultsmentioning

confidence: 99%

“…Evidence supporting the faecal microbiota composition as a predictor of therapeutic response in IBD is accumulating. Both the relative abundance of several (most frequently butyrate‐producing) microbiota species and functional pathway analysis may accurately predict response to anti‐TNF, VDZ and UST treatment . This area warrants further research and microbiome data need to be incorporated into multi‐omics analyses.…”

Section: Discussionmentioning

confidence: 99%

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy

Stevens

Matheeuwsen

Lönnkvist

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. Aim To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. Methods An electronic literature search was performed on 30 January 2018 using MEDLINE, EMBASE and the Cochrane Library. Retrospective, prospective, uncontrolled and controlled studies reporting on biomarkers predicting therapeutic response in paediatric and adult IBD populations were eligible for inclusion. The methodological quality of the included studies was assessed using the QUIPS tool. Due to anticipated heterogeneity and limited data, a qualitative, rather than quantitative, assessment was planned. Results Of the 10 638 citations identified, 92 articles met the inclusion criteria. Several potential DNA, mRNA and protein markers were evaluated as predictive biomarkers. Most studies focused on predicting response to anti‐TNF agents. Substantial between‐study heterogeneity was identified with respect to both the biomarkers studied and the definition of response. None of the included studies received a low risk of bias rating for all six domains. Currently, none of the biomarkers is sufficiently predictive for clinical use. Conclusions The search for predictive biomarkers is still in its infancy and current evidence is limited. Future research efforts should take into account the high patient heterogeneity within prospective trials with objective response assessment. Predictive models will most likely comprise a combination of several molecular markers from integrated omics‐levels and clinical characteristics.

show abstract

“…176 The retrospective case reports of pediatric patients with IBD found that vedolizumab tended to be slower acting and have lower remission rates in patients with CD compared to those with ulcerative colitis. 177,178 Long-term, open-label follow-up data report low rates of infusion reactions, serious infections, and malignancy. 179,180 The consensus group did not make a recommendation for or against the use of vedolizumab in patients who had failed prior anti-TNF therapy.…”

Section: No Consensus Mmentioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease

et al. 2019

View full text Add to dashboard Cite

Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease

Cited by 102 publications

References 13 publications

Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease

Contact Info

Product

Resources

About